Tim Anderson
Stock Analyst at B of A Securities
(4.41)
# 314
Out of 4,876 analysts
34
Total ratings
80%
Success rate
12.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $521.00 | +4.99% | 2 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $171 → $159 | $152.01 | +4.60% | 5 | Apr 10, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $13.86 | +87.59% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $107.62 | +17.08% | 3 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $279.11 | +5.33% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $186.79 | +19.39% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $28.71 | +32.36% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $27.54 | +23.46% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $78.83 | +42.08% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $24.24 | +19.64% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $46.65 | +35.05% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $126.92 | +40.25% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $795.12 | +25.39% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $120.32 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.07 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $521.00
Upside: +4.99%
Johnson & Johnson
Apr 10, 2025
Maintains: Neutral
Price Target: $171 → $159
Current: $152.01
Upside: +4.60%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $13.86
Upside: +87.59%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $107.62
Upside: +17.08%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $279.11
Upside: +5.33%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $186.79
Upside: +19.39%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $28.71
Upside: +32.36%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $27.54
Upside: +23.46%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $78.83
Upside: +42.08%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $24.24
Upside: +19.64%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $46.65
Upside: +35.05%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $126.92
Upside: +40.25%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $795.12
Upside: +25.39%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $120.32
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $70.07
Upside: -